Dr. Cragun is an assistant professor at the University of Arizona. She specializes in the diagnosis and treatment of gynecologic cancers such as endometrial and ovarian cancers as well as rare reproductive cancers, abnormal pap smears, high-risk cancer screening and fertility preservation.
Before completing the gynecologic oncology fellowship program at the University of South Florida in Tampa, Dr. Cragun earned her medical degree at the University of Utah School of Medicine, Salt Lake City, Utah; completed a residency in obstetrics and gynecology at Duke University Medical Center, Durham, North Carolina, and pursued a post-doctoral research fellowship at H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Currently, gynecologic cancers account for about 12 percent of all cancers which affect US women. Ovarian cancer alone is the fifth most common cause of cancer death in women. Dr. Cragun’s recent research studies include gene expression in older versus younger women with ovarian cancers responsive to cisplatin, and microRNA associated with development of cisplatin resistance.
Dr. Cragun currently sits on the Scientific Review Committee of the University of Arizona Cancer Center (UACC). She participates in clinical trials opened by the gynecologic oncology division at the University of Arizona, including both cooperative studies through the NRG as well as investigator initiated trials. She has acted as the site PI some of these trials (GOG 252, GOG 225, GOG 86P). As a gynecologic oncologist she has both surgical and chemotherapeutic background. Dr. Cragun brings these experiences to the scientific review committee as they review studies proposed for the UACC.
Dr. Cragun specializes in the diagnosis and treatment of gynecologic cancers to include:
- Ovarian Cancer
- Uterine Cancer
- Cervical Cancer
- Vulvar, Vaginal Cancer
- Gestational Trophoblastic Disease
- Complicated Gynecologic Surgery
- Premalignant Conditions of Cervix, Uterus, Vulva
- Abnormal Pap Smears
- High-Risk Cancer Screening
- Fertility Preservation
- Second Opinions
Investigator initiated trial (PI)
The expression of selected micro RNA in cisplatin resistant ovarian cancer cell lines
10-0136-04 (GOG 86P)
A three arm randomized phase II of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage II or IVA, stage IVB, or recurrent endometrial cancer
10-0475-10 (GOG 00252)
A phase III clinical trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube and primary peritoneal carcinoma
Investigator Initiated Trial (Co-PI)
08-0015-04 Analysis of circulating tumor cells, circulating endothelial cells, and angiogenic factors in patients with breast, cervical, ovarian, and endometrial cancers - an exploratory study
10-0254-10 (GOG 0249)
A phase III trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high risk, early stage endometrial carcinoma
10-0315-04 (GOG 0256)
Prospective study of cognitive function during chemotherapy for front-line treatment in ovarian, primary peritoneal or fallopian tube cancer
10-0524-04 (SWOG 0904)
Randomized phase II study of docetaxel followed by vandetanib vs. docetaxel plus vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
1st place, Amgen Young Investigator Forum, Joint Cancer Conference of the Florida Universities, Orlando, FL, 2005